Matrix metalloproteinase and aggrecanase generated aggrecan fragments: Implications for the diagnostics and therapeutics of destructive joint diseases

Drug Development Research

Volumn 68, Issue 1, 2007, Pages 1-13

  Sumer, Eren U ^a   Qvist, Per ^a   Tankó, László B ^b  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

Author keywords

Aggrecanase; Destructive joint diseases; Matrix metalloproteinase

Indexed keywords

5 (N ISOBUTYL N METHYL)AMILORIDE; AGGRECANASE; BATIMASTAT; BIOLOGICAL MARKER; CIPEMASTAT; COLLAGENASE 3; DOXYCYCLINE; GELATINASE A; GELATINASE B; GLUCOSAMINE; ILOMASTAT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERSTITIAL COLLAGENASE; MARIMASTAT; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MINOCYCLINE; NEUTROPHIL COLLAGENASE; PROTEOGLYCAN; RETINOIC ACID; SB 703704; STROMELYSIN; TANOMASTAT; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; XS 309;

ARTICULAR CARTILAGE; DIAGNOSTIC TEST; EX VIVO STUDY; EXPLANT; EXTRACELLULAR MATRIX; HUMAN; IMMUNOCHEMISTRY; INFLAMMATION; JOINT DESTRUCTION; MONITORING; NONHUMAN; OSTEOARTHRITIS; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 34249933756     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20166     Document Type: Review

References (79)

1. Abbaszade I, Liu RQ, Yang F, Rossenfeld SA, Ross OH, Link JR, Ellis DM, Tortorella MD, Pratta MA, Hollis JM, Wynn R, Duke JL, Geroge HJ, Hillman MC Jr, Murphy K, Wiswall BH, Copeland RA, Decicco CP, Bruckner R, Nagase H, Itoh Y, Newton RC, Magolda RL, Trzaskos JM, Burn TC. 1999. Cloning and characterization of ADAMTS-1 an aggrecanase from the ADAMTS family. J Biol Chem 274:23443-23450.
2. Aigner T, McKenna L. 2002. Molecular pathology and pathobiology of osteoarthritic cartilage. Cell Mol Life Sci 59:5-18.
3. Altman RD. 2004. Pain relief in osteoarthritis: the rationale for combination therapy. J Rheumatol 31:5-7.
4. Arner EC, Pratta MA, Decicco CP, Xue CB, Newton RC, Trzaskos JM, Magolda RL, Tortorella MD. 1999. Aggrecanase. A target for the design of inhibitors of cartilage degradation. Ann NY Acad Sci 878:92-107.
5. Bendele A, McComb J, Gould T, McAbee T, Sennello G, Chlipala E, Guy M. 1999. Animal models of arthritis: relevance to human disease. Toxicol. Pathol 27:134-142.
6. Bursavich MG, Gilbert AM, Lombardi S, Georgiadis KE, Reifenberg E, Flannery CR, Morris EA. 2007. Synthesis and evaluation of aryl thioxothiazolidinone inhibitors of ADAMTS-5 (Aggrecanase-2). Bioorg Med Chem Lett 17:1185-1188.
7. Caterson B, Flannery CR, Hughes CE, Little CB. 2000. Mechanisms involved in cartilage proteoglycan catabolism. Matrix Biol 19: 333-344.
8. Chen TC, Hinton DR, Zidovetzki R, Hofman FM. 1998. Up-regulation of the cAMP/PKA pathway inhibits proliferation, induces differentiation, and leads to apoptosis in malignant gliomas. Lab Invest 78:165-174.
9. Chockalingam PS, Zeng W, Morris EA, Flannery CR. 2004. Release of hyaluronan and hyaladherins (aggrecan G1 domain and link proteins) from articular cartilage exposed to ADAMTS-4 (aggrecanase 1) or ADAMTS-5 (aggrecanase 2). Arthritis Rheum 50:2839-2848.
10. Clements KM, Price JS, Chambers MG, Visco DM, Poole AR, Mason RM. 2003, Gene deletion of either interleukin-1beta, interleukin-1beta-converting enzyme, inducible nitric oxide synthase, or stromelysin 1 accelerates the development of knee osteoarthritis in mice after surgical transection of the medial collateral ligament and partial medial meniscectomy. Arthritis Rheum 48:3452-3463.
11. Close DR. 2001. Matrix metalloproteinase inhibitors in rheumatic diseases. Ann. Rheum Dis 60:62-67.
12. Colnot C, Thompson Z, Miclau T, Werb Z, Helms JA. 2003. Altered fracture repair in the absence of MMP9. Development 130: 4123-4133.
13. Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Shea B, Wells G, Adachi J, Waldegger L, Guyatt G. 2002. Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev. 23:540-551.
14. Dean DD, Martel-Pelletier J, Pelletier JP, Howell DS, Woessner JF Jr. 1989. Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest 84:678-685.
15. Flannery CR, Lark MW, Sandy JD. 1992. Identification of a stromelysin cleavage site within the interglobular domain of human aggrecan. Evidence for proteolysis at this site in vivo in human articular cartilage. J Biol Chem 267:1008-1014.
16. Fosang AJ, Neame PJ, Last K, Murphy G, Hardingham TE, Hamilton JA. 1992. The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B. J Biol Chem 267:19470-19474.
17. Fosang AJ, Last K, Neame PJ, Murphy G, Knauper V, Tschesche H, Hughes CE, Caterson B, Hardingham TE. 1994. Neutrophil collagenase (MMP-8) cleaves at the aggrecanase site E373-A374 in the interglobular domain of cartilage aggrecan. Biochem J 304:347-351.
18. Fosang AJ, Last K, Gardiner P, Jackson DC, Brown L. 1995. Development of a cleavage-site-specific monoclonal antibody for detecting metalloproteinase- derived aggrecan fragments: detection of fragments in human synovial fluids. Biochem J 310:337-343.
19. Fosang AJ, Last K, Maciewicz RA. 1996. Aggrecan is degraded by matrix metalloproteinases in human arthritis. Evidence that matrix metalloproteinase and aggrecanase activities can be independent. J Clin Invest 98:2292-2299.
20. Fosang AJ, Last K, Stanton H, Weeks DB, Campbell IK, Hardingham TE, Hembry RM. 2000. Generation and novel distribution of matrix metalloproteinase-derived aggrecan fragments in porcine cartilage explants. J Biol Chem 275: 33027-33037.
21. Ghosh P. 1999. The pathobiology of osteoarthritis and the rationale for the use of pentosan polysulfate for its treatment. Semin Arthrit Rheum 28:211-267.
22. Gilbert AM, Bursavich MG, Lombardi S, Georgiadis KE, Reifenberg E, Flannery CR, Morris EA. 2006. 5-((1H-Pyrazol-4-yl)methylene)-2- thioxothiazolidin-4-one inhibitors of ADAMTS-5. Bioorg Med Chem Lett
23. Glasson SS, Askew R, Sheppard B, Carito B, Blanchet T, Ma HL, Flannery CR, Peluso D, Kanki K, Yang Z, Majumdar MK, Morris EA. 2005. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 434: 644-648.
24. Hardingham TE, Fosang AJ. 1995. The structure of aggrecan and its turnover in cartilage. J Rheumatol (Suppl) 43:86-90.
25. Hashimoto G, Aoki T, Nakamura H, Tanzawa K, Okada Y. 2001. Inhibition of ADAMTS4 (aggrecanase-1) by tissue inhibitors of metalloproteinases (TIMP-1, 2, 3 and 4). FEBS. Lett 494: 192-195.
26. Hidalgo M, Eckhardt SG. 2001. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl. Cancer Inst. 93: 178-193.
27. Hui W, Rowan AD, Richards CD, Cawston TE. 2003. Oncostatin M in combination with tumor necrosis factor alpha induces cartilage damage and matrix metalloproteinase expression in vitro and in vivo. Arthritis Rheum 48:3404-3418.
28. Iozzo RV, Murdoch AD. 1996. Proteoglycans of the extracellular environment: clues from the gene and protein side offer novel perspectives in molecular diversity and function. FASEB J 10: 598-614.
29. Karsdal MA, Sumer EU, Wulf H, Høgh Madsen S, Fosang AJ, Christiansen C, Sondergaard BC. 2007. Induction of increased cAMP levels blocks matrix metallo proteinase but not aggrecanase mediated cartilage degrdation. Arthritis Rheum.
30. Kashiwagi M, Tortorella M, Nagase H, Brew K. 2001. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J Biol Chem 276:12501-12504.
31. Kiani C, Chen L, Wu YJ, Yee AJ, Yang BB. 2002. Structure and function of aggrecan. Cell Res 12:19-32.
32. Kloppenburg M, Mattie H, Douwes N, Dijkmans BA, Breedveld FC. 1995. Minocycline in the treatment of rheumatoid arthritis: relationship of serum concentrations to efficacy. J Rheumatol 22: 611-616.
33. Knudson CB, Knudson W. 2001. Cartilage proteoglycans. Semin Cell Dev Biol 12:69-78.
34. Kontogiorgis CA, Papaioannou P, Hadjipavlon-Litina DJ. 2005. Matrix Metalloproteinase inhibitors: a review on pharmacophore mapping and (q) sars results. Curr Med Chem 12:339-355.
35. Kuno K, Terashima Y, Matsushima K. 1999. ADAMTS-I is an active metalloproteinase associated with the extracellular matrix. J Biol Chem 274:18821-18826.
36. Lark MW, Bayne EK, Flanagan J, Harper CF, Hoerrner LA, Hutchinson NI, Singer H, Donatelli SA, Weidner JR, Williams HR, Mumford RA, Lohmander LS. 1997. Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. J Clin Invest 100:93-106.
37. Little CB, Flannery CR, Hughes CE, Mort JS, Roughley PJ, Dent C, Caterson B. 1999. Aggrecanase versus matrix metalloproteinases in the catabolism of the interglobular domain of aggrecan in vitro. Biochem J 344 Pt 1:61-68.
38. Little CB, Flannery CR, Hughes CE, Goodship A, Caterson B. 2005. Cytokine induced metalloproteinase expression and activity does not correlate with focal susceptibility of articular cartilage to degeneration. Osteoarthrit Cartil 13:162-170.
39. Loulakis P, Shrikhande A, Davis G, Maniglia CA. 1992. N-terminal sequence of proteoglycan fragments isolated from medium of interleukin-I-treated articular-cartilage cultures. Putative site(s) of enzymic cleavage. Biochem J 284:589-593.
40. Malemud CJ, Goldberg VM. 1999. Future directions for research and treatment of osteoarthritis. Front Biosci 4:D762-D771.
41. Malemud CJ, Papay RS, Hering TM. 1996. Forskolin stimulates aggrecan gene expression in cultured bovine chondrocytes. Am J Ther 3:120-128.
42. Malfait AM, Liu RQ, Ijiri K, Komiya S, Tortorella MD. 2002. Inhibition of ADAM-TS4 and ADAM-TS5 prevents aggrecan degradation in osteoarthritic cartilage. J Biol Chem 277: 22201-22208.
43. Manicourt DH, Azria M, Mindeholm L, Devogelear JP. 2005. Efficacy of calcitonin therapy in patients with knee osteoarthritis: a clinical and biochemical preliminary study. Osteoarthrit Cartil 13:88.
44. Mathews RT, Gary SC, Zerillo C, Pratta M, Solomon K, Arner EC, Hockfield S. 2000. Brain-enriched hyaluronan binding (BEHAB)/ brevican cleavage in a glioma cell line is mediated by a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) family member. J Biol Chem 275:22695-22703.
45. Mercuri FA, Maciewicz RA, Tart J, Last K, Fosang AJ. 2000. Mutations in the interglobular domain of aggrecan alter matrix metalloproteinase and aggrecanase cleavage patterns. Evidence that matrix metalloproteinase cleavage interferes with aggrecanase activity. J Biol Chem 275:33038-33045.
46. Munteanu SE, Ilie MZ, Handley CJ. 2000. Calcium pentosan polysulfate inhibits the catabolism of aggrecan in articular cartilage explain cultures. Arthrit Rheum 43:2211-2218.
47. Munteanu SE, Ilie MZ, Handley CJ. 2002. Highly sulfated glycosaminoglycans inhibit aggrecanase degradation of aggrecan by bovine articular cartilage explant cultures. Matrix Biol 21: 429-440.
48. Nagase H, Kashiwagi M. 2003. Aggrecanases and cartilage matrix-degradation, Arthritis Res Ther 5:94-103.
49. Nagase H, Meng Q, Malinovskii V, Huang W, Chung L, Bode W, Maskos K, Brew K. 1999. Engineering of selective TIMPs. Ann NY Acad Sci 878:1-11.
50. Noe MC, Natarajan V, Snow SL, Wolf-Gouveia LA, Mitchell PG, Lopresti-Morrow L, Reeves LM, Yocum SA, Otterness I, Bliven MA, Carty TJ, Barberia JT, Sweeney FJ, Liras JL, Vaughn M, 2005. Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13. Bioorg. Med Chem Lett 15:3385-3388.
51. Pratta MA, Su JL, Leesnitzer MA, Struglics A, Larsson S, Lohmander LS, Kumar S. 2006. Development and characterization of a highly specific and sensitive sandwich ELISA for detection of aggrecanase-generated aggrecan fragments. Osteoarthrit Cartil 14:702-713.
52. Rodriguez-Manzaneque JC, Westling J, Thai SN, Luque A, Knäuper V, Murphy G, Sandy JD, Iruela-Arispe ML. 2002. ADAMTS-1cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors. Biochem Biophys Res Commun 293:501-508.
53. Sandy JD. 2006. A contentious issue finds some clarity: on the independent and complementary roles of aggrecanase activity and MMP activity in human joint aggrecanolysis. Osteoarthritis Cartilage 14:95-100.
54. Sandy JD, Flannery CR, Neame PJ, Lohmander LS. 1992. The structure of aggrecan fragments in human synovial fluid. Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu 373-Ala 374 bond of the interglobular domain. J Clin Invest 89:1512-1516.
55. Sandy JD, Westling J, Kenagy RD, Iruela-Arispe ML, Verscharen C, Rodriguez Mazaneque JC, Zimmermann DR, Lemire JM, Fischer JW, Wright TN, Clowes AW. 2001. Versican V1 proteolysis in human aorta in vivo occurs at the Glu441-Ala442 bond a site that is cleaved by recombinant ADAMTS-1 and ADAMTS-4. 2001. J Biol Chem 276:13372-13378.
56. Schaller S, Henriksen K, Hoegh-Andersen P, Sondergaard BC, Sumer EU, Tanko LB, Qvist P, Karsdal MA. 2005. In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? Assay Drug Dev Technol 3:553-580.
57. Sexton PM, Findlay DM, Martin TJ. 1999. Calcitonin. Curr Med Chem 6:1067-1093.
58. Sondergaard BC, Wulf H, Henriksen K, Schaller S, Oestergaard S, Qvist P, Tanko LB, Bagger YZ, Christiansen C, Karsdal MA. 2006. Calcitonin directly attenuates collagen type II degradation by inhibition of matrix metalloproteinase expression and activity in articular chondrocytes. Osteoarthrit Cartil 14:759-768.
59. Song RH, Tortorella D, Malfait AM, Alston JT, Yang Z, Arner EC, Griggs DW. 2007. Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5. Arthritis Rheum 56:575-585.
60. Stanton H, Rogerson FM, East CJ, Golub SB, Lawlor KE, Meeker CT, Little CB, Last K, Farmer PJ, Campbell IK, Fourie AM, Fosang AJ. 2005. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature 434:648-652.
61. Struglics A, Larsson S, Pratta MA, Kumar S, Lark MW, Lohmander LS. 2006. Human osteoarthritis synovial fluid and joint cartilage contain both aggrecanase- and matrix metalloproteinase-generated aggrecan fragments. Osteoarthritis Cartilage 14:101-113.
62. Sugimoto K, Iizawa T, Harada H, Yamada K, Katsumata M, Takahashi M. 2004. Cartilage degradation independent of MMP/ aggrecanase. Osteoarthritis and Cartilage 12:1006-1014.
63. Sumer EU, Schaller S, Sondergaard BC, Tanko LB, Qvist P. 2006. Application of biomarkers in the clinical development of new drugs for chondroprotection in destructive joint diseases: a review. Biomarkers 11:485-506.
64. Sumer EU, Sondergaard BC, Rousseau JC, Delmas PD, Fosang AJ, Karsdal MA, Christiansen C, Qvist P. 2007. MMP and non-MMP-mediated release of aggrecan and its fragments from articular cartilage: a comparative study of three different aggrecan and glycosaminoglycan assays. Osteoarthrit Cartil 15:212-221.
65. Sztrolovics R, White RJ, Roughley PJ, Mort JS. 2002. The mechanism of aggrecan release from cartilage differs with tissue origin and the agent used to stimulate catabolism. Biochem J 362:465-472.
66. Takizawa M, Ohuchi E, Yamanaka H, Nakamura H, Ikeda E, Ghosh P, Okada Y. 2000. Production of tissue inhibitor of metalloproteinases 3 is selectively enhanced by calcium pentosan polysulfate in human rheumatoid synovial fibroblasts. Arthritis Rheum 43:812-820.
67. Tilley BC, Alarcon GS, Heyse SP, Trentham DE, Neuner R, Kaplan DA, Clegg DO, Leisen JC, Buckley L, Cooper SM, Duncan H, Pillemer SR, Tuttleman M, Fowler SE. 1995. Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Ann. Intern Med 122:81-90.
68. Tortorella MD, Pratta MA, Fox JW, Arner EC. 1998. The interglobular domain of cartilage aggrecan is cleaved by hemorrhagic metalloproteinase HT-d (atrolysin C) at the matrix metalloproteinase and aggrecanase sites. J Biol Chem 273: 5846-5850.
69. Tortorella MD, Burn TC, Pratta MA, Abbaszade I, Hollis JM, Liu R, Rosenfeld SA, Copeland RA, Decicco CP, Wynn R, Rockwell A, Yang F, Duke JL, Solomon K, George H, Bruckner R, Nagase H, Itoh Y, Ellis DM, Ross H, Wiswall BH, Murphy K, Hillman MC Jr, Hollis GF, Arner EC. 1999. Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science 284:1664-1666.
70. Uitterlinden EJ, Jahr H, Koevoet JL, Jenniskens YM, Bierma-Zeinstra SM, Degroot J, Verhaar JA, Weinans H, van Osch GJ. 2006. Glucosamine decreases expression of anabolic and catabolic genes in human osteoarthritic cartilage explants. Osteoarthrit Cartil 14:250-257.
71. Vankemmelbeke MN, Holen I, Wilson AG, Ilic MZ, Handley CJ, Kelner GS, Clark M, Liu C, Maki RA, Burnett D, Buttle DJ. 2001. Expression and activity of ADAMTS-5 in synovium. Eur J Biochem 268:1259-1268.
72. Vazquez F, Hastings G, Ortega MA, Lane TF, Oikemus S, Lombardo M, Iruela-Arispe ML. 1999. METH-1 a human ortholog of ADAMTS-1 and METH-2 are members of a new family of proteins with angioinhibitory activity. J Biol Chem 274:23349-23357.
73. Walakovits LA, Moore VL, Bhardwaj N, Gallick GS, Lark MW. 1992. Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury. Arthritis Rheum 35:35-42.
74. Whittaker M, Floyd CD, Brown P, Gearing AJH. 1999. Design and therapeutic application of matrix metallo proteinase inhibitors. Chem Rev 99:2735-2776.
75. Xiang JS, Hu Y, Rush TS, Thomason JR, Ipek M, Sum PE, Abrous L, Sabatini JJ, Georgiadis K, Reifenberg E, Majumdar M, Morris EA, Tam S. 2006. Synthesis and biological evaluation of biphenylsulfonamide carboxylate aggrecanase-I inhibitors. Bioorg Med Chem Lett 16:311-316.
76. Yao W, Wasserman ZR, Chao M, Reddy G, Shi E, Liu RQ, Covington MB, Arner EC, Pratta MA, Tortorella M, Magolda RL, Newton R, Qian M, Ribadeneira MD, Christ D, Wexler RR, Decicco CP. 2001. Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H- inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors. J Med Chem 44:3347-3350.
77. Yip D, Ahmad A, Karapetis CS, Hawkins CA, Harper PG. 1999. Matrix metalloproteinase inhibitors: applications in oncology. Invest New Drugs 17:387-399.
78. Yu AE, Hewitt RE, Connor EW, Stetler-Stevenson WG. 1997. Matrix metalloproteinases. Novel targets for directed cancer therapy. Drugs Aging 11:229-244.
79. Zhou Z, Apte SS, Soininen R, Cao R, Baaklini GY, Rauser RW, Wang J, Cao Y, Tryggvason K. 2000. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci USA 97:4052-4057.